• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Syros Pharmaceuticals (NQ: SYRS )

    6.060 +0.260 (+4.48%)
    Streaming Delayed Price Updated: 12:43 PM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 17,162
    Open 5.900
    Bid (Size) 6.040 (4)
    Ask (Size) 6.100 (8)
    Prev. Close 5.800
    Today's Range 5.710 - 6.082
    52wk Range 2.090 - 8.170
    Shares Outstanding 20,595,503
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
    From Syros Pharmaceuticals
    Via Business Wire

    Performance

    YTD
    -22.70%
    -22.70%
    1 Month
    +4.30%
    +4.30%
    3 Month
    +19.53%
    +19.53%
    6 Month
    -8.60%
    -8.60%
    1 Year
    +72.16%
    +72.16%

    More News

    Read More
    SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Pharmaceuticals's Earnings Outlook
    Via Benzinga
    Syros to Participate in Upcoming Investor Conferences
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
    From Syros Pharmaceuticals
    Via Business Wire
    Crude Oil Down Over 1%; Cognyte Software Shares Plummet
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    Top 3 Health Care Stocks You'll Regret Missing This Month
    Via Benzinga
    SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
    From Syros Pharmaceuticals
    Via Business Wire
    Earnings Scheduled For March 27, 2024
    Via Benzinga
    Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
    From Syros Pharmaceuticals
    Via Business Wire
    A Look Into Healthcare Sector Value Stocks
    Via Benzinga
    Syros to Participate in TD Cowen 44th Annual Health Care Conference
    From Syros Pharmaceuticals
    Via Business Wire
    Overview Of Value Stocks In The Healthcare Sector
    Via Benzinga
    3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
    Via InvestorPlace
    5 Value Stocks To Watch In The Healthcare Sector
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
    From Syros Pharmaceuticals
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.